Regnase-1 Prevents Pulmonary Arterial Hypertension Through mRNA Degradation of Interleukin-6 and Platelet-Derived Growth Factor in Alveolar Macrophages.
Ai YakuTadakatsu InagakiRyotaro AsanoMakoto OkazawaHiroyoshi MoriAyuko SatoFabian HiaTakeshi MasakiYusuke ManabeTomohiko IshibashiAlexis VandenbonYoshinari NakatsukaKotaro AkakiMasanori YoshinagaTakuya UehataTakashi MinoSatoshi MoritaHatsue Ishibashi-UedaAkio MorinobuTohru TsujimuraTakeshi OgoYoshikazu NakaokaOsamu TakeuchiPublished in: Circulation (2022)
Regnase-1 maintains lung innate immune homeostasis through the control of IL-6 and platelet-derived growth factor in alveolar macrophages, thereby suppressing the development of PAH in mice. Furthermore, the decreased expression of Regnase-1 in various types of PH implies its involvement in PH pathogenesis and may serve as a disease biomarker, and a therapeutic target for PH as well.